With 84% of HCPs now preferring digital or hybrid interactions, the question for pharmaceutical companies is no longer whether to adopt a digital-first engagement strategy. The real challenge in 2026 is whether the scientific content powering those digital interactions is compelling enough to earn attention and build trust.
The most important distinction between healthcare content partners is often overlooked entirely. Marketing-led agencies start with brand objectives and campaign goals before building content around those priorities. Science-led agencies begin with the evidence itself. For healthcare professional engagement, that difference in starting point has significant implications for scientific credibility, audience trust, and long-term communication effectiveness.
Many pharmaceutical teams continue to approach each content asset as a separate project and the result is duplicated effort, inconsistent messaging, longer approval cycles, and increased pressure on already stretched medical affairs and communications teams. The challenge in 2026 is no longer creating scientific content. It is scaling it efficiently. Leading organisations are moving away from asset-by-asset production and towards a scientific narrative approach that allows one evidence base to power dozens of content outputs
Many pharma organisations treat scientific communications and health advertising as interchangeable — but they are built on fundamentally different foundations. Discover why the distinction matters and why a science-first approach is becoming essential for HCP trust and credibility
Full-service agencies and specialist content partners solve very different problems. Find out which model best fits your pharma or biotech organisation’s scientific communication needs and why choosing the wrong one costs more than you think.
For many organisations, AI promises efficiency, faster output, and the ability to personalise communication across channels. However, scaling volume alone does not automatically translate into greater engagement or trust.
In the pharmaceutical industry, the conversation around silos usually focuses on data fragmented datasets, disconnected systems, and isolated research pipelines.
The Content Crisis, the Trust Shift and the Case for Co-Creation. The key takeaways from Reuters Pharma Europe 2026 and Pharma meets AI (UBIQ Events)
Dana Vigier, VP and Central and Northern Europe Area Head at Alexion, AstraZeneca Rare Disease, shares her views on a holistic approach to rare diseases. She emphasises the importance of listening to the voices of rare disease patients and ensuring they have access to the best treatment options.
In an exclusive interview with Michelle Melka, Director of Global Product Strategy, Digital Transformation at BioMarin, we delve into the changing landscape of pharmaceutical marketing. Melka emphasizes the importance of a patient-centric approach and highlights how BioMarin is evolving its digital capabilities to meet customer preferences. Learn about the challenges faced in providing accurate and accessible information, especially in the realm of rare diseases. Melka also discusses the company’s ambitions for powerful digital transformation and the future of content and omnichannel strategies in building meaningful relationships with healthcare professionals. Don’t miss the insights from this industry leader as she shares her vision for the future of pharma marketing.